15:19:54 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-14 Bokslutskommuniké 2024
2024-11-08 Kvartalsrapport 2024-Q3
2024-08-23 Kvartalsrapport 2024-Q2
2024-05-16 Kvartalsrapport 2024-Q1
2024-05-13 Ordinarie utdelning HBC 0.00 NOK
2024-05-10 Årsstämma 2024
2024-02-09 Bokslutskommuniké 2023
2024-01-04 Extra Bolagsstämma 2024
2023-11-10 Kvartalsrapport 2023-Q3
2023-08-25 Kvartalsrapport 2023-Q2
2023-05-12 Kvartalsrapport 2023-Q1
2023-05-02 Ordinarie utdelning HBC 0.00 NOK
2023-04-28 Årsstämma 2023
2023-02-10 Bokslutskommuniké 2022
2022-11-11 Kvartalsrapport 2022-Q3
2022-08-30 Extra Bolagsstämma 2022
2022-08-26 Kvartalsrapport 2022-Q2
2022-05-06 Kvartalsrapport 2022-Q1
2022-05-02 Ordinarie utdelning HBC 0.00 NOK
2022-04-29 Årsstämma 2022
2022-02-04 Bokslutskommuniké 2021
2021-12-03 Extra Bolagsstämma 2021
2021-11-05 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-05-21 Kvartalsrapport 2021-Q1
2021-04-26 Ordinarie utdelning HBC 0.00 NOK
2021-04-23 Årsstämma 2021
2021-02-05 Bokslutskommuniké 2020
2020-11-11 Extra Bolagsstämma 2020
2020-10-30 Kvartalsrapport 2020-Q3
2020-08-28 Kvartalsrapport 2020-Q2
2020-05-26 Ordinarie utdelning HBC 0.00 NOK
2020-05-25 Årsstämma 2020
2020-05-15 Kvartalsrapport 2020-Q1
2020-02-07 Bokslutskommuniké 2019
2019-11-01 Kvartalsrapport 2019-Q3
2019-08-30 Extra Bolagsstämma 2019
2019-08-30 Kvartalsrapport 2019-Q2
2019-05-10 Kvartalsrapport 2019-Q1
2019-04-29 Ordinarie utdelning HBC 0.00 NOK
2019-04-26 Årsstämma 2019
2019-02-08 Bokslutskommuniké 2018
2018-11-02 Kvartalsrapport 2018-Q3
2018-07-16 Extra Bolagsstämma 2018
2018-05-09 Kvartalsrapport 2018-Q1
2018-04-30 Ordinarie utdelning HBC 0.00 NOK
2018-04-27 Årsstämma 2018
2018-03-16 Bokslutskommuniké 2017
2017-11-15 Kvartalsrapport 2017-Q3
2017-08-25 Kvartalsrapport 2017-Q2
2017-05-25 Årsstämma 2017
2017-05-12 Kvartalsrapport 2017-Q1
2017-02-17 Bokslutskommuniké 2016
2016-11-18 Kvartalsrapport 2016-Q3
2016-09-20 Extra Bolagsstämma 2016
2016-08-31 Kvartalsrapport 2016-Q2
2016-05-20 Årsstämma 2016
2016-05-20 Kvartalsrapport 2016-Q1
2016-02-18 Bokslutskommuniké 2015
2015-11-13 Kvartalsrapport 2015-Q3
2015-08-13 Kvartalsrapport 2015-Q2
2015-05-22 Årsstämma 2015
2015-04-30 Kvartalsrapport 2015-Q1
2015-03-27 Bokslutskommuniké 2014
2014-05-02 Extra Bolagsstämma 2014
2013-12-27 Extra Bolagsstämma 2013
2013-06-13 Kapitalmarknadsdag 2013
2012-10-31 Kvartalsrapport 2012-Q3
2012-08-22 Kvartalsrapport 2012-Q2
2012-05-25 Kvartalsrapport 2012-Q1
2012-02-29 Bokslutskommuniké 2011

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriBioteknik
Hofseth BioCare är ett norskt bolag verksamma inom bioteknik. Bolaget utvecklar diverse högkvalitativt protein- och kalciumpulver, samt laxolja. Genom användandet av patenterad teknik kan bolaget i tidigt stadium utvinna ämnen för produktion. Produkterna levereras i form av kosttillskott och säljs via hälsobutiker. Bolaget grundades 2009 och har sitt huvudkontor i Ålesund.
2024-03-14 12:12:20

Kristin Fjellby Grung, Chair of the Board of Hofseth BioCare ASA, has informed the Board of Directors that she will resign from the position on 31 March 2024, as she will assume a position as judge in the District Court of Møre and Romsdal and will therefore not be able to continue to serve in the position as Chair of the Board.

Grung has been a member of the Board of Directors since December 2020, and assumed the position as Chair in April 2022. The Board would like to thank Grung for her services for Hofseth BioCare in this period.

Appointment of a new Chair of the Board will be proposed to the Company's annual general meeting, to be held on 10 May 2024. In the interim period, Roger Hofseth will function as the Chair of the Board of Directors.

For further information, please contact:
Jon Olav Ødegård, CEO at HBC
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no

About Hofseth BioCare ASA:

HBC is a Norwegian consumer and pet health ingredient supplier and an incubator for new pharmaceutical drug leads.  Research is ongoing to identify the individual elements within its ingredients that modulate inflammation and the immune response with pre-clinical studies ongoing in multiple clinics and university research labs. Lead clinical and pre-clinical candidates are focused on developing an oral treatment for inflammatory disease driven by eosinophils (a type of white blood cell). Clinical trial work with the oil is ongoing to ameliorate lung inflammation in eosinophilic asthma and COPD ("smokers lung").

Other leads are focused on using the Company's bioactive peptides as a Medical Food   for the protection of the Gastro- Intestinal (GI) system against inflammation (including ulcerative colitis and the orphan condition necrotizing enterocolitis). The Company is founded on the core values of sustainability, optimal   utilization of natural resources and full traceability.  Through innovative and patent protected hydrolysis technology, HBC can preserve the quality of the lipids, proteins and calcium from fresh salmon off-cuts.

HBC's headquarters are in Ålesund, Norway with offices in Oslo, London, Zürich, New Jersey and Palo Alto, CA.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.